Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H13NO3 |
Molecular Weight | 255.2686 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(O)=O)C1=CC2=C(OC3=NC=CC=C3C2)C=C1
InChI
InChIKey=TVQZAMVBTVNYLA-UHFFFAOYSA-N
InChI=1S/C15H13NO3/c1-9(15(17)18)10-4-5-13-12(7-10)8-11-3-2-6-16-14(11)19-13/h2-7,9H,8H2,1H3,(H,17,18)
DescriptionCurator's Comment: description was created based on several sources, including
https://www.unitedpharmacies.com/Niflan-Pranoprofen.html
Curator's Comment: description was created based on several sources, including
https://www.unitedpharmacies.com/Niflan-Pranoprofen.html
Pranoprofen, brand name Niflan, belongs to a class of medications called non steroidal anti-inflammatory drugs (NSAID). It can be used to treat inflammation, keratitis, conjunctivitis and blepharitis after eye surgery. Its mechanism of action is the inhibition of inflammatory prostaglandin synthesis. Prostaglandins are types of lipids which are produced at the site of injury or damaged tissue as part of the body`s response to the injury. They are responsible for inflammation. However, the main ingredient in this ophthalmic medicine is a non-steroidal anti-inflammatory drug, and by blocking the formation of prostaglandins, it can alleviate eye inflammation caused by keratitis, blepharitis and other conditions. Patients who have undergone surgery on the eyes may also be given it to prevent the occurrence of eye inflammation.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001516 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Niflan Approved Usecan treat swelling in the eyes caused by conjunctivitis |
|||
Primary | Niflan Approved UseUnknown |
|||
Primary | Niflan Approved UseUnknown |
|||
Primary | Niflan Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of topical anti-inflammatory and antiallergic eyedrops on prostaglandin E2-induced aqueous flare elevation in pigmented rabbits. | 2002 Jul |
|
Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. | 2002 Jul |
|
Capillary electrophoresis with laser induced-fluorescence detection of profens derivatized with the water-soluble fluorogenic reagent 4-N-(4-N'-aminoethyl)piperazino-7-nitro-2,1,3-benzoxadiazole. | 2003 Sep 5 |
|
Topical ocular delivery of NSAIDs. | 2008 Jun |
|
Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. | 2008 Oct 31 |
|
Collagen cross-linking with riboflavin and ultraviolet-A light in keratoconus: One-year results. | 2009 Jan |
|
Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model. | 2009 Mar |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. | 2010 Sep 20 |
|
Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. | 2014 |
Sample Use Guides
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/24641202
PPF (Pranoprofen) at concentrations ranging from 0.0625 to 1.0 g/l had poignant cytotoxicity to human corneal endothelial (HCE) cells, and the extent of its cytotoxicity was dose- and time-dependent. Further characterization indicated that PPF induced plasma membrane permeability elevation, DNA fragmentation, and apoptotic body formation, proving its apoptosis inducing effect on HCE cells. In conclusion, PPF above 0.0625 g/l has poignant cytotoxicity on HCE cells in vitro by inducing cell apoptosis, and should be carefully employed in eye clinic.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
||
|
WHO-ATC |
S01BC09
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
||
|
WHO-VATC |
QS01BC09
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C73092
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
2R7O1ET613
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
SUB10000MIG
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
759832
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
100000081398
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
m9101
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB13514
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
PRANOPROFEN
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
DTXSID1023497
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
4298
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
2238
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL367463
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
4888
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY | |||
|
52549-17-4
Created by
admin on Fri Dec 15 18:44:22 GMT 2023 , Edited by admin on Fri Dec 15 18:44:22 GMT 2023
|
PRIMARY |
ACTIVE MOIETY